文献速递贫血与红细胞疾病

铁蛋白指导的铁剂补充作为延长献血间隔的替代或补充方案(FORTE):一项双盲、随机、对照试验

Ferritin-guided iron supplementation as an alternative or complement to prolonged blood donation intervals (FORTE): a double-blind, randomised, controlled trial.
PubMed 文献 · Lancet Haematol · 2025-08-14

在荷兰七个献血中心开展的双盲随机安慰剂对照试验中,830例铁蛋白≤30 μg/L的献血者随机接受56天不同方案铁剂补充或安慰剂。第56天时,各铁剂组铁缺乏、低铁蛋白和低血红蛋白的比值比均显著低于每日安慰剂组,60 mg每日方案效果尤为突出。作者认为铁剂补充是低铁蛋白全血献血者延长献血间隔的有效替代或补充方案。

要点

  • 铁蛋白≤30 μg/L的献血者补充铁剂56天可降低铁缺乏、低铁蛋白和低血红蛋白风险。
  • 与每日安慰剂相比,各铁剂方案铁缺乏的OR为0.60至0.65。
  • 60 mg每日方案在降低低铁蛋白方面OR为0.52,效果尤为突出。

核心结论

  • 在铁蛋白低的定期献血者中,铁剂补充(尤其是60 mg每日)可有效减轻铁缺乏、低铁蛋白和低血红蛋白。
  • 铁剂补充是低铁蛋白全血献血者延长献血间隔的有效替代或补充方案。

研究设计与样本

  • 双盲、随机、安慰剂对照试验,在荷兰七个Sanquin献血中心开展。
  • 纳入18-80岁、铁蛋白≤30 μg/L的献血者830例,按性别和年龄区组随机等数分配至六个研究组。
  • 干预为连续56天服用双甘氨酸亚铁胶囊,元素铁剂量为0 mg(安慰剂)、30 mg或60 mg,每日或隔日服用。
  • 主要结局为第56天随访时铁缺乏(<15 μg/L)、低铁蛋白(15-30 μg/L)和低血红蛋白(男性≤135 g/L,女性≤125 g/L)的存在情况,采用意向性治疗分析。
  • 试验注册于荷兰试验注册库(NL7328.018.20),已完成。

主要发现

  • 2021年8月1日至2023年1月15日期间,830例低铁蛋白献血者(女性464例[56%],男性366例[44%];荷兰裔789例[95%],非荷兰裔26例[3%])纳入试验。
  • 第56天铁缺乏发生率:安慰剂每日组108例中55例(51%),安慰剂隔日组119例中58例(49%),30 mg每日组107例中11例(10%),30 mg隔日组112例中8例(7%),60 mg每日组114例中1例(1%),60 mg隔日组110例中4例(4%)。
  • 与每日安慰剂相比,铁缺乏的OR:30 mg每日组0.62(95%CI 0.56-0.68),30 mg隔日组0.63(95%CI 0.57-0.70),60 mg每日组0.60(95%CI 0.55-0.66),60 mg隔日组0.65(95%CI 0.59-0.72)。
  • 低铁蛋白的OR:30 mg每日组0.70(95%CI 0.63-0.78),30 mg隔日组0.82(95%CI 0.74-0.91),60 mg每日组0.52(95%CI 0.47-0.57),60 mg隔日组0.61(95%CI 0.55-0.68)。
  • 低血红蛋白的OR:30 mg每日组0.78(95%CI 0.67-0.91),30 mg隔日组0.80(95%CI 0.68-0.93),60 mg每日组0.75(95%CI 0.64-0.86),60 mg隔日组0.77(95%CI 0.66-0.90)。

临床怎么用

  • 作者认为,对于铁蛋白低的定期献血者,铁剂补充(尤其是60 mg每日)可有效减轻铁缺乏、低铁蛋白和低血红蛋白。
  • 作者认为,铁剂补充是低铁蛋白全血献血者延长献血间隔的有效替代或补充方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Regular blood donation is associated with an increased risk of iron deficiency and anaemia. Oral iron supplementation is known to shorten post-donation iron recovery time and could serve as an alternative to extended donation intervals. We aimed to evaluate the effect of different iron supplementation protocols on ferritin and haemoglobin levels, gastrointestinal side-effects, iron deficiency-related symptoms, and donor return compared with placebo supplementation. METHODS: In this double-blind, randomised, placebo-controlled trial conducted at seven of Sanquin's blood donation centres in The Netherlands, donors aged 18-80 years with ferritin levels equal to or less than 30 μg/L were randomly allocated to one of six study groups, using block randomisation in equal numbers by sex and age. Donors were instructed to adhere to a ferrous bisglycinate supplementation protocol for 56 days, taking capsules containing 0 mg (placebo), 30 mg, or 60 mg of elemental iron, either daily or on alternate days. The primary outcomes were presence of iron deficiency (<15 μg/L), low ferritin (15-30 μg/L), and low haemoglobin (≤135 g/L for male donors and ≤125 g/L for female donors) at 56 days' follow-up. Analyses were conducted using an intention-to-treat approach. This trial is registered in the Dutch trial registry (NL7328.018.20) and is complete. FINDINGS: Between Aug 1, 2021, and Jan 15, 2023, 830 donors (464 [56%] female donors and 366 [44%] male donors; 789 [95%] of Dutch origin and 26 [3%] of non-Dutch origin) had low ferritin and were included in the trial. At 56 days, 55 (51%) of 108 participants in the placebo daily group, 58 (49%) of 119 participants in the placebo alternate day group, 11 (10%) of 107 participants in the 30 mg daily group, eight (7%) of 112 participants in the 30 mg alternate day group, one (1%) of 114 participants in the 60 mg daily group, and four (4%) of 110 participants in the 60 mg alternate day group presented with iron deficiency. Compared with daily placebo, all iron supplementation groups exhibited similar significantly lower odds of iron deficiency at 56 days, with odds ratios (ORs) of 0·62 (95% CI 0·56-0·68) for 30 mg daily, 0·63 (0·57-0·70) for 30 mg alternative days, 0·60 (0·55-0·66) for 60 mg daily, and 0·65 (0·59-0·72) for 60 mg on alternative days. For low ferritin, 0·70 (0·63-0·78) for 30 mg daily, 0·82 (0·74-0·91) for 30 mg on alternative days, 0·52 (0·47-0·57) for 60 mg daily, and 0·61 (0·55-0·68) for 60 mg on alternate days. For low haemoglobin, the ORs were 0·78 (0·67-0·91) for 30 mg daily, 0·80 (0·68-0·93) for 30 mg on alternative days, 0·75 (0·64-0·86) for 60 mg daily, and 0·77 (0·66-0·90) for 60 mg alternative days. Adverse events were reported in two participants-one event, an increase in migraines, was considered potentially related to the study intervention, but the other (a death) was deemed unrelated. INTERPRETATION: In regular donors with low ferritin, iron supplementation-60 mg taken daily, in particular-effectively mitigates iron deficiency, low ferritin, and low haemoglobin. Iron supplementation is an effective alternative or supplement to extended donation intervals for whole-blood donors with low ferritin levels. FUNDING: Sanquin Blood Supply Foundation. TRANSLATION: For the Dutch translation of the abstract see Supplementary Materials section.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Karregat JHM, Meulenbeld A, Quee FA, et al. Ferritin-guided iron supplementation as an alternative or complement to prolonged blood donation intervals (FORTE): a double-blind, randomised, controlled trial. Lancet Haematol. 2025. PMID: 40819648. doi:10.1016/S2352-3026(25)00167-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。